EF 27

Drug Profile

EF 27

Alternative Names: Amelorad; So 5407

Latest Information Update: 17 Mar 1998

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Scotia Pharmaceuticals [CEASED]
  • Class Antineoplastics; Radioprotectives
  • Mechanism of Action Prostaglandin synthase stimulants; Thromboxane synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Radiation injuries

Most Recent Events

  • 17 Mar 1998 Scotia has withdrawn EF 27 license application in Europe
  • 23 Feb 1998 Discontinued-Clinical for Radiation injuries (Prevention)/Radioprotection in European Union (Unknown route)
  • 23 Feb 1998 Discontinued-Clinical for Radiation injuries (Prevention)/Radioprotection in South Africa (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top